TRKing down an old oncogene in a new era of targeted therapy.
TRKing down an old oncogene in a new era of targeted therapy.
复制标题
DOI：
10.1158/2159-8290.cd-14-0765
复制
发表时间：
2015-01
期刊：
影响因子：
28.2
通讯作者：
Doebele RC
中科院分区：
文献类型：
--
作者：
Vaishnavi A;Le AT;Doebele RC
在过去几年中，在多种肿瘤类型中采用高通量下一代测序技术，迄今已在19种不同肿瘤类型中鉴定出编码新型致癌融合的NTRK 1、2和3基因重排。这些最近的发展使我们重新审视了一个古老的癌基因Trk（最初被鉴定为OncD），它编码TPM 3-NTRK 1基因融合，是32年前发现的首批转化性染色体重排之一。然而，美国FDA尚未批准任何药物用于携带这种致癌基因的癌症。这篇综述将讨论Trk家族受体的生物学，它们在人类癌症中的作用，致癌改变的类型，以及目前正在开发的针对该家族癌基因靶点的药物。
The employment of high-throughput next-generation sequencing techniques in multiple tumor types during the last few years has identified NTRK1, 2, and 3 gene rearrangements encoding novel oncogenic fusions in 19 different tumor types to date. These recent developments have led us to revisit an old oncogene, Trk, (originally identified as OncD), which encodes the TPM3-NTRK1 gene fusion and was one of the first transforming chromosomal rearrangements identified 32 years ago. However, no drug has yet been approved by the US FDA for cancers harboring this oncogene. This review will discuss the biology of the Trk family of receptors, their role in human cancer, the types of oncogenic alterations, and drugs that are currently in development for this family of oncogene targets.